Orexigen Therapeutics announces data from CORDiabetes trial for Contrave

Orexigen Therapeutics announces data from CORDiabetes trial for Contrave
Orexigen Therapeutics, Inc. today announced data from the CORDiabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) showing that after 56 weeks of treatment, overweight or obese patients with type 2 diabetes lost significantly more weight and achieved greater improvement in glycemic control than those treated with placebo.

Read more on News-Medical-Net